
ELCC 2022
CONTENTS
Online First
Early-Stage Non-Small Cell Lung Cancer

Real-world treatment and survival in early-stage NSCLC
Consistent efficacy of osimertinib in Chinese and global population

Promising efficacy of neoadjuvant osimertinib in EGFR-mutated NSCLC
Peri-operative survival in bilobectomy is comparable with that of left pneumonectomy
Advanced Non-Small Cell Lung Cancer
Pro-inflammatory tumour profile predicts complete pathological response to neoadjuvant chemoimmunotherapy

Furmonertinib outperforms gefitinib as first-line therapy in patients with EGFR-mutated NSCLC
Second-line oritinib demonstrated potential clinical benefit in advanced EGFR-mutated NSCLC
Updated results confirm efficacy and safety of entrectinib in patients with NTRK fusion-positive NSCLC
ROS1 rearrangement-targeting unecritinib is a potential new first-line strategy
Savolitinib is effective in patients with MET-mutated NSCLC
Sintilimab plus chemotherapy improves OS in treatment-naïve, stage III–IV non-squamous NSCLC

Updated results of CameL-sq trial confirm benefit of camrelizumab
No long-term benefit of adding ipilimumab to pembrolizumab in metastatic NSCLC
In concurrent CRT for stage III, unresectable NSCLC, performance status is better with proton therapy than photon therapy
No improved prognosis for concurrent versus sequential immune checkpoint inhibition and CRT in unresectable NSCLC
Durvalumab after sequential CRT safe in stage III, unresectable NSCLC
No impact of grade ≥2 pneumonitis on patient-reported outcomes in PACIFIC

Immunotherapy delays deterioration in health-related quality of life in metastatic NSCLC
Small Cell Lung Cancer
Total metabolic tumour volume: a new potential prognostic factor in SCLC
Radiation dose on oesophagus predicts OS in SCLC patients treated with chemoradiotherapy
Characteristics of long-term survivors in the CASPIAN trial
